
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Trial dropouts and study findings: Getting the analysis right/Cultural similarities, cultural differences/Gloves for vaccinations? The jury is split






